Eli Lilly and Co.'s Reyvow, or lasmiditan, gained FDA approval for the treatment of acute migraine, giving the company a second drug for treatment of migraine following last year's approval of Emgality, or galcanezumab. The drug will not be available to patients until after Drug Enforcement Administration classification, expected in the next three months.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.